About Adenylate cyclase type 3
Adenylate cyclase type 3 (ADCY3) is a protein
from Homo sapiens identified by UniProt accession
O60266, 1144 residues long.
MolForge cross-references it against 0 known binders and
215 disease associations.
Target properties
| Protein name | Adenylate cyclase type 3 |
|---|
| UniProt accession | O60266 |
|---|
| Gene | ADCY3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1144 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (215)
Diseases linked to this target (Open Targets).
- obesity · score 0.52
- body mass index · score 0.49
- inherited obesity · score 0.46
- body fat percentage · score 0.43
- body height · score 0.43
- physical activity measurement · score 0.43
- reticulocyte count · score 0.41
- diastolic blood pressure · score 0.41
- fat body mass · score 0.40
- Crohn's disease · score 0.40
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60266-F1 | alphafold | PREDICTED | 76.39 | — |
Amino-acid sequence (1144 residues)
MPRNQGFSEP EYSAEYSAEY SVSLPSDPDR GVGRTHEISV RNSGSCLCLP RFMRLTFVPE SLENLYQTYF KRQRHETLLV LVVFAALFDC YVVVMCAVVF SSDKLASLAV AGIGLVLDII LFVLCKKGLL PDRVTRRVLP YVLWLLITAQ IFSYLGLNFA RAHAASDTVG WQVFFVFSFF ITLPLSLSPI VIISVVSCVV HTLVLGVTVA QQQQEELKGM QLLREILANV FLYLCAIAVG IMSYYMADRK HRKAFLEARQ SLEVKMNLEE QSQQQENLML SILPKHVADE MLKDMKKDES QKDQQQFNTM YMYRHENVSI LFADIVGFTQ LSSACSAQEL VKLLNELFAR FDKLAAKYHQ LRIKILGDCY YCICGLPDYR EDHAVCSILM GLAMVEAISY VREKTKTGVD MRVGVHTGTV LGGVLGQKRW QYDVWSTDVT VANKMEAGGI PGRVHISQST MDCLKGEFDV EPGDGGSRCD YLEEKGIETY LIIASKPEVK KTATQNGLNG SALPNGAPAS SKSSSPALIE TKEPNGSAHS SGSTSEKPEE QDAQADNPSF PNPRRRLRLQ DLADRVVDAS EDEHELNQLL NEALLERESA QVVKKRNTFL LSMRFMDPEM ETRYSVEKEK QSGAAFSCSC VVLLCTALVE ILIDPWLMTN YVTFMVGEIL LLILTICSLA AIFPRAFPKK LVAFSTWIDR TRWARNTWAM LAIFILVMAN VVDMLSCLQY YTGPSNATAG METEGSCLEN PKYYNYVAVL SLIATIMLVQ VSHMVKLTLM LLVAGAVATI NLYAWRPVFD EYDHKRFREH DLPMVALEQM QGFNPGLNGT DRLPLVPSKY SMTVMVFLMM LSFYYFSRHV EKLARTLFLW KIEVHDQKER VYEMRRWNEA LVTNMLPEHV ARHFLGSKKR DEELYSQTYD EIGVMFASLP NFADFYTEES INNGGIECLR FLNEIISDFD SLLDNPKFRV ITKIKTIGST YMAASGVTPD VNTNGFASSN KEDKSERERW QHLADLADFA LAMKDTLTNI NNQSFNNFML RIGMNKGGVL AGVIGARKPH YDIWGNTVNV ASRMESTGVM GNIQVVEETQ VILREYGFRF VRRGPIFVKG KGELLTFFLK GRDKLATFPN GPSVTLPHQV VDNS
Explore Adenylate cyclase type 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets